R/R NKTL represents a unique and challenging subtype of non-Hodgkin lymphoma, distinguished by its rarity and aggressive clinical course. Current therapeutic regimens offer limited efficacy, especially for patients who have relapsed after initial treatments or demonstrate resistance to standard approaches. Anti-PD-1 (programmed cell death protein 1) immune checkpoint blockade has emerged as a hopeful strategy by reactivating the immune system’s capacity to recognize and eradicate tumor cells. Despite encouraging responses, many patients ultimately exhibit therapeutic resistance or relapse, highlighting the urgent need to elucidate resistance mechanisms and enhance treatment modalities.

The central innovation presented by this study rests on priming the tumor microenvironment with DNMT inhibitors — drugs that reverse aberrant epigenetic silencing by inhibiting DNA methyltransferases. This epigenetic perturbation reactivates endogenous retroviral elements (ERVs), which are vestigial viral sequences inserted into the human genome through ancient infections. When re-expressed, these ERVs simulate a viral infection within the tumor cells, triggering an innate immune response termed viral mimicry. The activation of this viral mimicry pathway galvanizes the type 1 interferon signaling cascade, a crucial mediator of antiviral defense, culminating in enhanced recruitment and activation of cytotoxic CD8-positive T cells within the tumor microenvironment.

The research team, led by principal investigators Drs. Jing Tan, Huiqiang Huang, and Choon Kiat Ong, retrospectively analyzed clinical outcomes and mechanistic insights derived from 21 patients with R/R NKTL who had initially responded to anti-PD-1 therapy but subsequently developed disease progression. These patients were administered a combinational regimen of the PD-1 inhibitor sintilimab alongside one of two DNMT inhibitors — decitabine or azacitidine — both clinically established agents known for their epigenetic modulation capacities. The results were compelling: nearly half achieved complete remission, with additional patients experiencing partial responses; notably, the two-year overall survival rate was a remarkable 50.2%, a substantial improvement over historical data.

The study’s preclinical investigations using murine models underscored the molecular underpinnings of therapy resistance and reversal. DNMT inhibition effectively demethylated and reactivated ERVs within tumor cells, engendering a potent type 1 interferon response. This immunogenic cascade remodeled the tumor microenvironment, mitigating immune evasion and facilitating robust infiltration of CD8-positive cytotoxic T lymphocytes, which are essential for effective antitumor immunity. These insights establish a mechanistic rationale for combining epigenetic therapy with immune checkpoint blockade, offering a synergistic approach to overcoming immune resistance.

Clinicians and researchers alike herald these findings as a transformative step toward personalized immunotherapy in hematologic malignancies. Dr. Huang highlighted the clinical impact, noting that the observed median overall survival represented a striking improvement over previous benchmarks where patients showing progression post-PD-1 blockade typically faced median survival of only around three months. This combination therapy holds potential curative promise for a subset of patients, indicating that strategically reversing epigenetic silencing may re-sensitize tumors to immunotherapy and reshape treatment paradigms.

Further amplifying the significance of this work, the study delineates the pivotal role of viral mimicry as a therapeutic lever. By engaging ancient viral elements latent within the genome, the immune system is effectively tricked into mounting an antiviral-like assault on the tumor, sidestepping conventional mechanisms of immune suppression. This viral mimicry concept aligns with emerging evidence across diverse cancer types, where epigenetic therapies augment immunotherapeutic responses by “unmasking” tumors otherwise cloaked from immune surveillance.

However, the investigation also acknowledges substantive limitations deserving of caution and future inquiry. The retrospective design and limited patient cohort constrain the generalizability of the findings and emphasize the necessity for prospective, larger-scale clinical trials to validate efficacy and safety comprehensively. NKTL’s rarity further complicates patient recruitment and detailed tumor microenvironment profiling, which is critical for tailoring optimized combination strategies. Moreover, while the murine models recreated key features of acquired resistance observed in patients, the precise immune landscape dynamics within human NKTL tumors remain insufficiently characterized and warrant deeper exploration.

Funding from prominent scientific bodies including the National Natural Science Foundation of China and Singapore’s National Medical Research Council underscores the collaborative and international nature of this research endeavor. Importantly, the authors have declared no conflicts of interest, enhancing the credibility and objectivity of their work.

This landmark study illuminates the promising frontier where epigenetics converges with immuno-oncology, spotlighting viral mimicry as a compelling strategy to surmount immune resistance in malignancies. Beyond NKTL, the concept portends transformative potential across a spectrum of tumor types historically refractory to immunotherapy. As research evolves, refining these combination regimens and unraveling the complexities of tumor-immune interactions will be vital to unlocking broader clinical benefit.

In summary, the integration of DNMT inhibitors with anti-PD-1 antibodies inaugurates a new era in lymphoma treatment, harnessing the immune system’s intrinsic antiviral defenses to galvanize powerful antitumor activity. This innovative approach not only improves survival outcomes for a devastating cancer but also exemplifies the creative therapeutic avenues emerging at the intersection of genomics, epigenetics, and immunology. The oncology community eagerly anticipates further validation and expansion of these findings, which signify a beacon of hope for patients grappling with relapsed or refractory NK/T-cell lymphoma.

Subject of Research: Combination epigenetic therapy with anti-PD-1 immunotherapy in relapsed/refractory natural killer/T-cell lymphoma

Article Title: Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma

News Publication Date: 15-Oct-2025

Web References: DOI: 10.1158/2159-8290.CD-25-0587

Keywords: Cancer immunology, Immunotherapy, Lymphoma

Enter Lingyin Li, PhD, a biochemist and professor at Stanford University’s Department of Biochemistry and the ChEM-H institute, whose groundbreaking work explores a novel immunotherapeutic strategy aimed at converting these “cold” solid tumors into “hot,” immunologically active ones. Unlike traditional immunotherapies that primarily stimulate the adaptive immune response, Dr. Li’s approach harnesses a powerful mechanism of the innate immune system centered on the small molecule cyclic GMP-AMP (cGAMP). As a rapid responder to cellular damage and pathogenic threats, cGAMP triggers immediate inflammatory signaling through the STING (stimulator of interferon genes) pathway, acting as a first line of defense.

One of the pivotal discoveries made by Li’s lab unveiled that tumors evade immune surveillance not only by silencing adaptive immunity but also by actively degrading cGAMP through overexpression of the enzyme ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). ENPP1 catalyzes the hydrolysis of extracellular cGAMP, effectively preventing it from activating STING pathways in surrounding immune cells. This degradation maintains the tumor’s cold microenvironment, allowing malignant cells to proliferate unchecked. Understanding this molecular camouflage mechanism framed the hypothesis that inhibiting ENPP1 could bolster innate immune signaling within tumors and enhance anti-cancer immunity.

Capitalizing on this insight, Dr. Li and her interdisciplinary team synthesized STF-1623, a potent and selective small-molecule inhibitor of ENPP1. This drug is designed to specifically bind to and block ENPP1 activity localized on the tumor cell surface, thereby preserving cGAMP levels within the tumor microenvironment. Their recent publication in Cell Reports Medicine (September 2025) provides compelling preclinical evidence that STF-1623 amplifies intratumoral cGAMP concentrations, which in turn activate the STING pathway in immune cells, transforming inert tumors into hotbeds of immunological activity.

In meticulous in vivo studies employing multiple mouse models—covering breast, pancreatic, colorectal, and glioblastoma cancers—STF-1623 demonstrably suppressed tumor growth without eliciting detectable adverse effects. This selective safety profile results from the drug’s mechanism of targeting ENPP1, which is highly concentrated on tumor cells but expressed at minimal levels in healthy tissues. Consequently, STF-1623 primarily acts where it is needed, mitigating systemic inflammation and associated toxicities often observed with broader immune activators.

At the molecular level, structural biology elucidated the intimate interaction between STF-1623 and ENPP1. The inhibitor occupies the enzyme’s active site, coordinating with essential zinc ions and displaying long-term binding affinity exceeding 24 hours. This durable engagement potentiates sustained inhibition of cGAMP hydrolysis, thus amplifying the persistence of cGAMP signaling in the tumor milieu. This mechanism sets STF-1623 apart from conventional STING agonists, which attempt to directly stimulate the pathway, often resulting in unrestrained inflammation and limited clinical success.

Moreover, STF-1623’s mode of action leverages endogenous cGAMP produced by cancer cells in response to genomic instability—a hallmark of tumors characterized by DNA damage and mutation burden. Cytosolic DNA leaks from the nucleus or mitochondria activate the DNA sensor cGAS, catalyzing cGAMP synthesis. However, cancer cells exploit ENPP1 to evade this innate alert system, thereby dampening immune activation. By neutralizing ENPP1, STF-1623 reinstates this ancient surveillance checkpoint, mobilizing innate immune effectors including type I interferons, dendritic cells, and natural killer cells to mount a robust anti-tumor assault.

Despite the promise of STF-1623 as a monotherapy, Dr. Li emphasizes that the inherent complexity of cancer necessitates combination strategies. Preclinical data indicate enhanced efficacy when STF-1623 is administered alongside other cancer therapies such as checkpoint inhibitors or chemotherapies. This combinatorial approach may synergistically unmask tumors to immune detection, improve infiltration of cytotoxic lymphocytes, and overcome resistance mechanisms. Such targeted activation of innate immunity at the tumor site could complement the systemic adaptive immune engagement fostered by existing immunotherapies.

Another notable advantage of STF-1623 arises from its ability to finely tune the immune response by preserving physiological cGAMP signaling, rather than artificially activating STING with synthetic agonists. This nuanced modulation of innate immunity is expected to reduce off-target effects and excessive inflammation that have plagued early clinical trials with direct STING agonists. By working with the body’s natural defense mechanisms, STF-1623 represents a paradigm shift in designing immunotherapies that precisely recalibrate tumor-immune interactions.

With promising preclinical efficacy and an encouraging safety profile, STF-1623 has recently obtained FDA clearance to initiate Phase I clinical trials. Patient enrollment is anticipated to commence shortly, marking a significant milestone in the translation of innate immune checkpoint blockade from bench to bedside. These clinical studies will critically evaluate the drug’s safety, pharmacokinetics, and preliminary anti-cancer activity in humans, laying the groundwork for potential new treatment avenues for patients with cancers unresponsive to current immunotherapies.

Dr. Li’s pioneering work at the Arc Institute, an independent nonprofit dedicated to accelerating biomedical discovery through collaborative and curiosity-driven research, exemplifies the transformative potential of innovative immune-targeted drug design. Supported by both public and private funders such as the National Institutes of Health and Angarus Therapeutics, this research integrates structural biology, immunology, and translational science to confront one of oncology’s most stubborn challenges: treating the invisible, immune-evading cold tumors.

As the field moves forward, the success of STF-1623 could inspire a broader class of innate immune checkpoint inhibitors, expanding the therapeutic arsenal against solid tumors. By illuminating the intricate crosstalk between cancer cells and the innate immune system, Dr. Li’s research ushers in a new era—one where the body’s first responders are empowered to rally a powerful, localized immune offense against elusive malignancies.

Subject of Research: Animals

Article Title: Innate immune checkpoint blockade with an ENPP1 inhibitor boosts intratumoral cGAMP to drive anti-cancer immunity

News Publication Date: 5-Sep-2025

Web References:
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00409-4

References:
Wang S., Johnson R., Carozza J., Fernandez D., Scicinski J., Verity N., Mardjuki R., Cao X., Guo Y., Papkoff J., Ray N., Li L. (2025). Innate immune checkpoint blockade with an ENPP1 inhibitor boosts intratumoral cGAMP to drive anti-cancer immunity. Cell Reports Medicine. DOI: 10.1016/j.xcrm.2025.102336

Image Credits: Raymond Rudolph

Keywords: Cancer, Biomedical engineering, Drug design

Tumor microenvironments are often characterized by regions of hypoxia due to rapid cell proliferation outpacing blood supply. This oxygen deprivation, far from simply inducing cell death, paradoxically equips cancer stem cells with survival advantages. Central to this adaptive process is the activation of hypoxia-inducible factors (HIFs), transcriptional regulators that orchestrate a broad genetic reprogramming to endure harsh conditions. The current study meticulously deciphers how HIF-1 and HIF-2, two major isoforms, selectively activate a suite of genes that collectively drive breast cancer stemness, invasiveness, and immune responsiveness.

At the heart of this hypoxic response lies the transcriptional upregulation of the genes PLXNB3, NARF, and TERT, all under the direct regulation of HIF-1. PLXNB3, a critical player in this cascade, interacts directly with the MET receptor tyrosine kinase. MET is well-known for its role in cell motility and invasion, but the study reveals a fascinating linkage wherein PLXNB3-mediated MET activation triggers downstream signaling via the non-receptor tyrosine kinase SRC. SRC kinase functions as a molecular hub, further activating focal adhesion kinase (FAK), an enzyme indispensable for anchoring BCSCs within their niche and promoting migratory capabilities that potentiate metastasis.

The signaling network extends beyond motility; SRC also modulates STAT3 activation, which subsequently induces expression of NANOG, a pivotal transcription factor synonymous with stemness and pluripotency. This axis from PLXNB3 to MET to SRC and STAT3 to NANOG embodies a tightly controlled feedback loop fostering BCSC self-renewal and expansion under hypoxic conditions. The identification of these signaling intermediates spotlights potential therapeutic targets that may disrupt cancer stem cell maintenance without harming normal tissue.

Equally intriguing is the role of NARF, whose expression hinges exclusively on HIF-1α rather than HIF-2α, illustrating the isoform-specific nuances of hypoxic regulation. NARF functions as a coactivator for OCT4, another master transcription factor governing stem cell fate. Through this partnership, NARF amplifies expression of key pluripotency genes including KLF4, NANOG, and SOX2. This transcriptional network underscores a multifaceted reinforcement mechanism that hypoxia lays down to solidify the cancer stem cell phenotype, with OCT4 and its cofactors serving as nodal points in this adaptive landscape.

Remarkably, hypoxia-induced TERT expression uncovers a novel regulatory crosstalk between NANOG and the telomerase reverse transcriptase gene. NANOG binds to the HIF-1 recruitment site on the TERT promoter, effectively stabilizing HIF-1α and HIF-1β binding and enhancing telomerase activity critical for indefinite replication potential. The disruption of NANOG’s presence profoundly diminishes HIF-1 occupancy on the TERT promoter, highlighting a previously unappreciated cooperative mechanism in telomere maintenance and stemness preservation amid hypoxic stress.

Beyond these transcriptional adaptations, the study reveals that chronic hypoxia drives a distinct remodeling of breast cancer stemness through HIF-2α upregulation. Unlike the immediate genetic reprogramming governed by HIF-1, HIF-2α orchestrates a metabolic pivot aimed at mitigating oxidative damage by increasing expression of superoxide dismutase 2 (SOD2). This mitochondrial antioxidant enzyme effectively reduces mitochondrial reactive oxygen species (mtROS), lessening oxidative stress and avoiding apoptosis that often accompanies hypoxic injury.

The downstream consequences of reduced mtROS are profound. Lowered oxidative stress facilitates activation of the endoplasmic reticulum (ER) unfolded protein response sensor GRP78, also known as UPRER. This stress response not only promotes cancer cell survival under adverse microenvironmental conditions but also contributes to an additional layer of stemness remodeling. By fine-tuning proteostasis and cellular homeostasis, the UPRER pathway emerges as an important mediator of hypoxia-driven plasticity, allowing breast cancer stem cells to dynamically adapt and persist during treatment.

Collectively, these molecular insights offer a compelling picture of how hypoxia acts as a master regulator transforming breast tumors into more aggressive and treatment-resistant entities. The intricate interplay between HIF isoforms, transcription factors, and signaling kinases illustrates a robust network that sustains cancer stemness, promotes invasion, and evades immune surveillance. Importantly, the study’s identification of distinct yet convergent pathways suggests multiple potential intervention points for therapeutic exploitation.

One of the most exciting implications of this research lies in its potential to convert immunologically “cold” breast tumors—those that evade immune detection and respond poorly to immunotherapy—into “hot” tumors that are more vulnerable to immune attack. The hypoxia-driven stemness phenotype appears linked to enhanced immunogenicity, potentially by altering the tumor microenvironment and enabling stronger immune cell infiltration. This concept heralds a paradigm shift in breast cancer treatment, where harnessing hypoxia-induced molecular changes could sensitize tumors to checkpoint inhibitors and other immunomodulatory agents.

For clinicians and drug developers, this study signals a critical need to target the hypoxia-HIF axis and its downstream effectors to dismantle the reservoirs of breast cancer stem cells. Approaches could include inhibitors of MET, SRC, or FAK kinases, blockade of NANOG or OCT4 coactivation, or strategies to modulate TERT activity and mitochondrial ROS balance. Furthermore, the combined attenuation of HIF-1 and HIF-2 driven pathways may yield synergistic effects, crippling both the genetic and metabolic adaptations that allow BCSCs to thrive in hostile tumor milieus.

The exploration of such hypoxia-centered therapeutic strategies is particularly urgent given the persistent challenges in treating metastatic breast cancer and preventing relapse. Cancer stem cells have long been implicated in therapeutic resistance, and their enrichment under hypoxia underscores the need for multipronged approaches that disrupt the hypoxic niche itself as well as the progenitor cells it nurtures. This dual targeting may ultimately improve long-term patient outcomes and reduce mortality.

Beyond breast cancer, the revelations from this study likely carry profound significance for other solid tumors where hypoxia and cancer stem cells similarly drive progression and resistance. As such, the hypoxia-HIF-stemness nexus presents an alluring universal target, inspiring renewed efforts in cancer biology and pharmacology to develop next-generation therapies. Translating these molecular findings to clinical application will require sophisticated biomarker-driven trials to pinpoint patients who will benefit most from hypoxia-targeted interventions.

In conclusion, this pioneering research decodes the complex molecular choreography by which hypoxia empowers breast cancer stem cells, reshaping the tumor microenvironment and immune landscape. The delineation of HIF-1 and HIF-2 dependent axes involving PLXNB3-MET-SRC-FAK signaling, OCT4 coactivation by NARF, and telomerase regulation via NANOG unravels novel vulnerabilities ripe for therapeutic targeting. Moreover, chronic hypoxia-induced mitochondrial metabolic shifts invoking GRP78-UPRER activation reveal unsuspected layers of cancer stemness control. Together, these insights herald a new frontier in understanding tumor plasticity and resistance, bringing hope of more effective breast cancer immunotherapies on the horizon.

As breast cancer continues to claim lives globally, studies like this underscore the indispensable value of basic molecular research in uncovering the enigmatic behaviors of cancer stem cells and tumor microenvironments. By elevating hypoxia from a mere stress factor to a powerful architect of malignancy, researchers are charting a course toward treatments that can outwit cancer’s most tenacious cellular subpopulation. The future of breast cancer therapy may well hinge on our ability to decode and manipulate these hypoxic signaling networks, transforming patient prognoses and reimagining cancer care.

Subject of Research: Breast cancer stem cell expansion and stemness remodeling under hypoxic conditions

Article Title: Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy

Article References:
Liu, L., Wu, D., Qian, Z. et al. Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy. Cell Death Discov. 11, 381 (2025). https://doi.org/10.1038/s41420-025-02682-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02682-8

A team of researchers, led by Dr. Edgar Engleman, MD, PhD, at Stanford University, has uncovered that EPO, traditionally seen as a hematopoietic growth factor, functions as a critical switch within the immune landscape of cancer. The study, published in the prestigious journal Science on April 24, 2025, demonstrates that by blocking EPO signaling, formerly “cold” tumors—those that evade immune detection—can be converted into “hot” tumors, rich with activated cancer-fighting immune cells, particularly T lymphocytes. This transformation holds profound therapeutic implications, especially when combined with immune checkpoint inhibitors like anti-PD-1 antibodies, such as the commercially available Keytruda.

Cold tumors are a notorious challenge in oncology because their immune-resistant nature allows unchecked cancer growth. Dr. Engleman’s group utilized sophisticated genome editing techniques to develop multiple mouse models of liver cancer that closely mirror human disease, including its genetic mutations, histological features, and response patterns to existing therapies. Leveraging these models, they observed that tumors exhibiting resistance to anti-PD-1 therapy also showed markedly elevated levels of EPO compared to tumors infiltrated by immune cells. This correlation indicated a previously unappreciated role for EPO in fostering an immunosuppressive tumor microenvironment.

Further investigation revealed that tumor-associated hypoxia, a hallmark of many solid tumors, is a driving force behind the increased expression of EPO within cold tumors. Hypoxia stimulates cancer cells to produce signals that elevate EPO levels, which, in turn, act on macrophages within the tumor. These macrophages, once activated by EPO through its receptor, shift towards an immunosuppressive phenotype, actively repelling T cells and quelling their anti-cancer activities. This crosstalk essentially creates an immune-privileged niche, enabling tumors to grow unchecked and resist current immunotherapies.

Strikingly, when the researchers genetically disrupted the tumor cells’ ability to produce EPO, the formerly cold tumors transformed into hot, inflamed tumors, abundant with active T cells. Conversely, artificially elevating EPO levels in hot tumors induced immune suppression, enabling tumor progression. These elegant experiments solidify the causal role of tumor-derived EPO as an immunosuppressive switch, shifting the tumor-immune balance toward immune evasion.

To probe the therapeutic potential of these findings, the team evaluated the combined blockade of the EPO signaling pathway and PD-1. In murine models carrying cold liver tumors, neither anti-PD-1 therapy nor controls alone improved survival beyond eight weeks post tumor induction. However, mice engineered to have macrophages deficient in EPO receptors exhibited significantly extended survival, with 40% alive at 18 weeks after tumor initiation. Strikingly, when these macrophage-specific EPO receptor knockout mice received anti-PD-1 therapy, survival extended to the full duration of the experiment, with complete tumor regression in most cases.

These results underscore that interrupting EPO signaling effectively reactivates the immune system’s ability to recognize and destroy tumors, overcoming one of the major barriers in cancer immunotherapy. Dr. Engleman emphasized that targeting EPO or its receptor could complement existing checkpoint blockade therapies, thus widening the spectrum of cancers responsive to immunotherapy—particularly liver, pancreatic, colorectal, breast, and prostate cancers, which are typically resistant to anti-PD-1 therapy.

The clinical implications extend beyond liver cancer, as analyses of patient tumor databases revealed a consistent association between high EPO expression and poorer survival across multiple tumor types, including kidney, breast, colon, and skin cancers. This highlights EPO’s broader role as a central regulator within the tumor microenvironment’s immune modulation.

Despite the promise, Dr. Engleman cautions against indiscriminate systemic inhibition of EPO due to its essential physiological role in red blood cell production, raising concerns about anemia as a potential side effect. As an alternative, strategies are under exploration to selectively target EPO receptors expressed on tumor-associated macrophages, aiming to disrupt immunosuppression without compromising erythropoiesis. This targeted approach may offer a safer therapeutic window while enhancing immune-mediated tumor clearance.

This discovery also provides a mechanistic explanation for previous clinical observations that administration of EPO to cancer patients with anemia sometimes accelerated tumor growth—a phenomenon that had puzzled clinicians and researchers for years and led to FDA black box warnings on EPO drugs. By elucidating EPO’s immunosuppressive function within tumors, the study reconciles these clinical findings within a comprehensive biological framework.

The interdisciplinary collaboration for this research included contributions from the New York Blood Center and ImmunEdge Inc., a biotechnology company co-founded by Dr. Chiu, the study’s lead author, and Dr. Engleman. Their joint efforts exemplify how academic and industrial partnerships can accelerate the translation of basic scientific insights into therapeutic innovations.

Looking forward, Dr. Engleman and his team are advancing preclinical development of EPO pathway inhibitors and designing clinical strategies to test their efficacy in human cancers. The anticipated integration of EPO receptor blockade with immune checkpoint therapy holds promise to not only improve patient outcomes but also to expand the reach of immunotherapy to presently refractory cancers.

This pioneering research reshapes fundamental concepts in cancer immunity by unveiling an unexpected role for erythropoietin—a decades-old molecule—in modulating tumor immune escape. As the field embraces these insights, the future of cancer treatment may soon harness EPO-targeted strategies to reinvigorate anti-tumor immunity and bring new hope to patients worldwide.

Subject of Research: Animals

Article Title: Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity

News Publication Date: 24-Apr-2025